Clinical Scorecard: Revisiting Aldosterone Synthase Inhibitors for the Management of Cardiovascular and Renal Conditions
At a Glance
Category
Detail
Condition
Cardiovascular and renal diseases associated with inappropriate aldosterone excess
Key Mechanisms
Aldosterone excess causes target organ damage via mineralocorticoid receptor activation and nongenomic effects; aldosterone synthase inhibitors reduce aldosterone production by selectively inhibiting CYP11B2
Target Population
Patients with resistant hypertension, chronic kidney disease, heart failure, and proteinuric kidney disease
Care Setting
Outpatient and specialized cardiovascular and renal care settings
Key Highlights
Mineralocorticoid receptor antagonists (MRAs) like spironolactone improve outcomes but have tolerability and hyperkalemia risks limiting use.
Early phase II trials show ASIs reduce blood pressure and urinary albumin excretion; longer-term trials are ongoing to assess cardiovascular and renal benefits.
Guideline-Based Recommendations
Diagnosis
Identify resistant hypertension and proteinuric chronic kidney disease with evidence of aldosterone excess.
Assess renal function and potassium levels prior to MRA or ASI therapy.
Management
Use spironolactone as first-line MRA for resistant hypertension, considering dose 25-50 mg/day.
Consider eplerenone or newer nonsteroidal MRAs (e.g., finerenone) when spironolactone is not tolerated.
Emerging use of aldosterone synthase inhibitors as potential alternatives to MRAs, pending further trial results.
Monitoring & Follow-up
Regularly monitor serum potassium and renal function during MRA or ASI therapy.
Monitor blood pressure response and signs of hormonal side effects (e.g., gynecomastia with spironolactone).
Risks
Hyperkalemia risk increased in CKD patients, especially when combined with renin-angiotensin system blockers.
Spironolactone-associated sexual adverse effects due to non-selective receptor binding.
Potential incomplete blockade of aldosterone nongenomic effects by MRAs.
Patient & Prescribing Data
Patients with resistant hypertension, heart failure, and chronic kidney disease with proteinuria
Spironolactone is effective but underprescribed due to side effects; newer MRAs and ASIs offer improved selectivity and tolerability profiles with ongoing evaluation of long-term efficacy and safety.
Clinical Best Practices
Start with low-dose spironolactone in resistant hypertension, monitor for hyperkalemia and adverse effects.
Consider patient-specific factors such as renal function and tolerance when choosing between MRAs and emerging ASIs.
Be aware of the limitations of MRAs in blocking aldosterone’s nongenomic effects; ASIs may provide complementary benefits.
Use combination therapy including SGLT2 inhibitors as future strategies under investigation.
A prespecified exploratory analysis of the FIND-CKD clinical trial examined kidney function, albuminuria, and kidney failure outcomes in 903 patients with glomerular diseases.
